Mylan recalls more than 100,000 packages of Klonopin generic

Mylan is recalling more than 100,000 packages of clonazepam, its generic of Klonopin.

Even as generic drugmaker Mylan is dealing with a host of other issues, it is recalling more than 100,000 packages of clonazepam, its generic of Klonopin, a drug that is used to treat seizures and panic disorder.

According to the most recent FDA Enforcement reports, Mylan actually began the voluntary U.S. recall of clonazepam in September after discovering the product was out of spec for a known impurity at the 15 and 16 month testing periods. The report indicated they were manufactured at Mylan’s Morgantown, West Virginia, plant. The FDA only posted the recalls for two different strengths in the last week.

The company is recalling 1,182 unit dose cards of 300 tablets and 52,618 unit dose blister cards of the 0.5 mg tablets, along with another 46,472 unit dose blister cards of the 1.0 mg tablets.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

It turns out that at about the same time that Mylan began its recall, Health Canada issued a recall of 1 mg clonazepam tablets manufactured by Canadian company Pharmascience because the lot might also contain tablets of hypertension drug Terazosin-HCl.

The recall is the least of Mylan’s worries these days. The company’s price hikes on the EpiPen have led to a firestorm of controversy. It is currently trying to finalize a $465 million settlement with the Justice Department for Medicaid overcharges for the ephedrine injector.

RELATED: Think EpiPen is Mylan's first scandal? Here's a timeline of jet use, an unearned MBA and more

The company is also part of a different DOJ investigation, along with lots of other generic drug producers, into potential collusion on prices.

Suggested Articles

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.